Good News
businesswire.com
( BW)(CA-VIVUS)(VVUS) MUSE Receives Marketing Licenses in France, Norway, Austria and
Portugal; Astra AB to Pay $2 Million Milestone
Business Editors/Medical Writers
MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 18, 1999--VIVUS, Inc. (Nasdaq:VVUS) today announced that
the Company has received notification that the marketing license for MUSE(R) (alprostadil) in France has been granted.
This license triggers a $2 million milestone payment to VIVUS from ASTRA. In addition, Norway and the European Union
countries of Portugal and Austria have recently issued licenses for MUSE.
Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile
dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as
the transurethral system for erection. This therapy consists of a proprietary, non-invasive drug delivery system that delivers
pharmacologic agents via the urethra.
Note to editors and investors: Additional written materials, recent releases and Company information are available through
a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service
(1-888-329-5719).
--30--cs/sf*
CONTACT: VIVUS, Inc., Mountain View
Nina W. Ferrari, 650/934-5200
IR@VIVUS.com
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: MEDICINE PHARMACEUTICAL PRODUCT |
